We hypothesized that this is due to the abundance of PD-L1+ tumor cells that can block systemic CD8+ T-cell immunity induced by MLP treatment, but in a melanoma tumor model after treatment with MLPs plus anti-PD-1 inhibitors, a significant increase was recorded in survival in mice. Here, CD8A is linked to neoplasm.